| 2016-02 |
Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Oncology Research and Treatment. 2016 Feb;39(Suppl. 1):170. |
 |
| 2016-02 |
A randomized, open-label phase II study of nanoliposomal irinotecan (nal-IRI)-containing regimens versus nab-paclitaxel plus gemcitabine in patients with previously untreated metastatic pancreatic adenocarcinoma (mPAC) |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract TPS482. |
|
| 2016-02 |
Phase III study of nanoliposomal irinotecan (nal-IRI, MM-398), with or without 5-fluorouracil and leucovorin (5-FU/LV), versus 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 417. |
|
| 2016-02 |
Results of Phase II trial of AUY922, a novel heat shock protein inhibitor in patients with metastatic gastrointestinal stromal tumor (GIST) and imatinib and sunitinib therapy |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 134. |
|
| 2016-02 |
Phase I trial of biweekly S-1, leucovorin, oxaliplatin, and gemcitabine (the SLOG regimen) in metastatic pancreatic adenocarcinoma (mPDAC) |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 369. |
|
| 2016-02 |
Phase I dose-escalation study of sorafenib plus S-1 in refractory solid tumors |
Journal of Clinical Oncology. 2016 Feb;34(4, Suppl.):Meeting Abstract 745. |
|
| 2015-12 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma-TCOG 3211 clinical trial |
Journal of Gastroenterology and Hepatology. 2015 Dec;30(Suppl. S4):99. |
|
| 2015-09 |
The safety and efficacy of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan |
European Journal of Cancer. 2015 Sep;51(Suppl. 3):S459. |
|
| 2015-09 |
Expression of the Helicobater pylori CagA protein is closely associated with Helicobater pylori-dependence of early-stage high-grade gastric lymphoma |
European Journal of Cancer. 2015 Sep;51(Suppl. 3):S662. |
|
| 2015-08 |
The association between periodontal disease and pancreatic cancer |
Cancer Research. 2015 Aug;75:Abstract number 871. |
|
| 2015-05 |
Heterogeneous cell origin of helicobater pylori-dependent high-grade gastric lymphomas |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):e19520. |
|
| 2015-05 |
Randomized, phase III trial of adjuvant adeforvir vs. therapeutic lamivudine in post-operative BCLC stage 0 or A HBV-related HCC: The Taiwan Cooperative Oncology Group T1206 study |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4101. |
|
| 2015-05 |
A phase II study of sequential capecitabine plus oxaliplatin (XELOX) followed by docetaxel plus capecitabine (TX) in patients with unresectable gastric adenocarcinoma: The TCOG T3211 trial |
Journal of Clinical Oncology. 2015 May;33(15, Suppl.):4024. |
|
| 2015-01 |
Expanded analyses of napoli-1: Phase 3 study of MM-398 (nal-IRI), with or without 5-fluorouracil and leucovorin, versus 5-fluorouracil and leucovorin, in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy |
Journal of Clinical Oncology. 2015 Jan;33(3, Suppl. ):234. |
|
| 2014-12 |
Pegylated arginine deiminase (ADI-PEG20) in relapsed/refractory and/or elder Acute Myeloid Leukemia: The preliminary result of phase II trial |
Blood. 2014 Dec;124(21):984. |
|
| 2014-10 |
Nuclear expression of BCL10 has a role in the regulation of cell growth and progression of pancreatic cancer through the activation of NF-kappa B-related signaling |
Cancer Research. 2014 Oct;74(19 Suppl.):Abstract No. 4217. |
|
| 2014-05 |
Using chinese herbal medicine containing mu-tong is associated with upper urinary tract cancer in patient with end-stage renal disease |
Nephrology, Dialysis, Transplantation. 2014 May;29(Suppl. 3):iii65-iii67. |
|
| 2014-05 |
Randomized open-label phase 2 study of MM-111 and paclitaxel (PTX) with trastuzumab (TRAS) in patients with HER2-expressing carcinomas of the distal esophagus, gastroesophageal (GE) junction, and stomach who have failed front-line metastatic or locally ad |
Journal of Clinical Oncology. 2014 May;32(15, Suppl.):TPS4148. |
|
| 2014-05 |
Association of helicobacter pylori CagA translocation with the expression of CagA-signaling transduction molecules in gastric mucosa-associated lymphoid tissue lymphoma |
Journal of Clinical Oncology. 2014 May;32(15, Suppl.):8571. |
|
| 2014-05 |
High expression of Hsp90-beta and GRP 94 association with poor survival in resected non-small cell lung cancer patients |
Journal of Clinical Oncology. 2014 May;32(15, Suppl.):e13522. |
|
| 2014-05 |
A phase I dose escalation study of weekly BI 836845, a fully human, affinity-optineized, insulin -like growth factor (IGF) ligand neutralizing antibody, in patients with advanced solid cancers |
Journal of Clinical Oncology. 2014 May;32(15, Suppl.):2617. |
|
| 2014-01 |
EVOLVE-1: Phase 3 study of everolimus for advanced HCC that progressed during or after sorafenib |
Journal of Clinical Oncology. 2014 Jan;32(3 Suppl.):Abstract number 172 |
|
| 2014-01 |
Impact of ROS1, ALK, and/or MET expression level on the therapeutic efficacy of GEMOX with and without cetuximab in ABTC: A post hoc analysis of a randomized phase II trial |
Journal of Clinical Oncology. 2014 Jan;32(3 Suppl):Abstract number 267. |
|
| 2013-05 |
Effective treatment of aggressive B-cell lymphomas by downregulated NIK-induced noncanonical NF-kappa B pathway activation through inhibition of BAFF |
Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number e13554. |
|
| 2013-05 |
KRAS mutation status-stratified randomized phase II trial of GEMOX with and without cetuximab in advanced biliary tract cancer (ABTC): The TCOG T1210 trial |
Journal of Clinical Oncology. 2013 May;31(15 Suppl.):Abstract number 4018. |
|
